Moleculin Biotech, Inc. — Form 10-Q Summary
Reporting period: Quarter and nine months ended September 30, 2023. Filed November 13, 2023. Financial statements are unaudited. Moleculin is a Phase 2 clinical-stage pharmaceutical company developing candidates for difficult-to-treat cancers and viruses; it reported no revenue.
Financial results and liquidity
| Metric | Q3 2023 | Q3 2022 | Nine months 2023 | Nine months 2022 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Research and development expense | $3.28M | $5.97M | $12.86M | $14.79M |
| General and administrative expense | $2.64M | $3.09M | $7.77M | $8.70M |
| Total operating expenses | $5.95M | $9.08M | $20.71M | $23.59M |
| Net loss | $5.61M | $8.61M | $19.50M | $22.26M |
| Basic and diluted loss per share | $0.19 | $0.30 | $0.66 | $0.78 |
- Nine-month operating cash use was $18.69M, versus $20.38M in 2022. Investing cash use was $0.04M; financing provided $0.19M. Cash declined $18.57M to $24.58M.
- At September 30, 2023, current assets were $27.60M and current liabilities $3.89M. Total liabilities were $4.39M; the filing reports no debt borrowings. Cash and cash equivalents were $24.58M, down from $43.15M at year-end 2022.
- No operating margin is meaningful because the company had no revenue. The company recorded $1.11M interest income for the nine months, compared with $0.11M in 2022, and a $0.08M warrant-liability fair-value gain, compared with $1.18M.
Changes, developments, and outlook
- Lower R&D costs, attributed mainly to clinical-trial and sponsored-research timing, and lower G&A costs contributed to the smaller year-over-year net loss. Higher interest income also reduced the loss; the warrant fair-value gain was substantially smaller than in 2022.
- Management said September 30 cash was expected to fund planned operations, including current Phase 1B/2 programs and trial preparations, into the third quarter of 2024 without additional equity for cash. The filing nevertheless states that substantial doubt exists about the company’s ability to continue as a going concern: it has an accumulated deficit of $121.3M, no operating revenue, and depends on obtaining financing and achieving profitable operations. Additional financing is not assured.
- Clinical updates were preliminary. In the Annamycin/Cytarabine AML trial, the filing reported eight complete responses across Phase 1B and Phase 2 to date, with some response durability observed; the company planned to enroll up to 21 Phase 2 subjects and anticipated completing recruitment by early 2024. In the Annamycin soft-tissue sarcoma lung-metastasis trial, recruitment and treatment had concluded; median progression-free survival was reported as 2.2 months overall, with overall-survival data still developing. The company said fuller topline data were planned for 2024.
- The company reported an independent assessment finding no evidence of Annamycin-related cardiotoxicity in data from 62 subjects; this is company-reported clinical information, not a guarantee of future safety or efficacy.
- The company expects to pursue externally funded WP1066 trials and further development of WP1122, while noting that timing and funding remain uncertain. The filing identifies clinical, regulatory, manufacturing, financing, collaboration, intellectual-property, competition, and geopolitical/supply-chain risks.
Notable matters and contingencies
- In March 2023, Moleculin terminated its WPD sublicense agreement, paying $0.7M cash and issuing shares valued at $0.8M. It regained certain territorial rights and acquired related in-process research and development. WPD is affiliated with the company’s founder.
- An SEC subpoena received in March 2022 seeks information concerning certain individuals and entities and development and statements regarding the company’s COVID-19 candidate. The company says the investigation is ongoing, it does not know its specific nature, and it cannot predict its outcome. Related expenses were $1.4M for the first nine months of 2023. An insurance claim remained under review, with no reimbursement recorded.
- Nasdaq granted an extension through April 29, 2024 to regain the $1.00 minimum bid-price requirement. Stockholders authorized the Board to effect a 1-for-5 to 1-for-20 reverse split, but the Board had taken no action as of the filing. Failure to regain compliance could result in delisting proceedings.
- The corporate office lease was extended through August 2029. In October 2023, the company amended an MD Anderson sponsored-research agreement for $0.8M of payments through December 2025.
- Disclosure controls were assessed as effective at September 30, 2023; the filing reports no material change in internal control over financial reporting during the quarter and no material change to previously disclosed risk factors.
Investor verification priorities
- Confirm cash burn, financing needs, and whether subsequent funding or spending changes alter the stated runway and going-concern risk.
- Track Nasdaq bid-price compliance, any reverse-split decision, and the April 29, 2024 deadline.
- Verify subsequent AML and sarcoma trial results, enrollment and follow-up, and the status of planned 2024 data disclosures; treat preliminary company-reported findings cautiously.
- Monitor the SEC matter, legal costs, and whether insurance reimbursement is approved and recorded.
- Review dilution from equity issuances, options, restricted stock units, warrants, and any future financing; common shares outstanding were 29,810,443 at November 1, 2023.